Showing results (201-210 of 249) with videos related to

Sort By:
Pageof 25
Fetal Diagnosis and Therapy|March 1, 1995
Iatrogenic gastroschisis decreases pulmonary hypoplasia in an ovine congenital diaphragmatic hernia modelL D Montgomery, M A Belfort, G R Saade, et al.
The Journal of Knee Surgery|February 11, 2025
Patellar Overstuffing in Total Knee Arthroplasty Results in Decreased Extensor Mechanism EfficiencyBrandon R Bukowski, Sonia K Chandi, Pravjit Bhatti, et al.
Clinical Pharmacology and Therapeutics|March 7, 2007
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha familyP Masci, T Olencki, L Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Blood|August 8, 1998
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalphaW Ling, P Rayman, R Uzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancerR L Schilsky, R Bukowski, H Burris, et al.
Cancer Research|October 15, 1994
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary reportX Li, J Liu, J K Park, et al.
Investigational New Drugs|November 15, 2006
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumorsS Kalmadi, M Davis, A Dowlati, et al.
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
The T cell death knell: immune-mediated tumor death in renal cell carcinomaR G Uzzo, V Kolenko, C J Froelich, et al.
Pageof 25